A study to determine whether the use of SGLT2 inhibitors is associated with an increased fracture risk in patients with type 2 diabetes
Latest Information Update: 04 Nov 2019
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
Most Recent Events
- 04 Nov 2019 New trial record